Mito in the News


Stealth BioTherapeutics Presents Data for Elamipretide on Cardiac Function in Barth Syndrome

New data from open-label extension portion of TAZPOWER study demonstrated improved cardiac function BOSTON, Oct. 17, 2019 /PRNewswire/ — Stealth BioTherapeutics ( MITO ), a clinical-stage biotechnology company focused...


Stealth Biotherapeutics Shares Promising Data from Mitochondrial Myopathy Trial

July 19, 2017 Recently, at the 2017 UMDF Mitochondrial Medicine Symposium, Stealth BioTherapeutics shared very encouraging results from its second clinical trial for primary mitochondrial myopathy, the MMPOWER-2 study....


MitoAtion, the Foundation for Mitochhondrial Medicine and UMDF Jointly Authored Editorial

MitoAction, the Foundation for Mitochondrial Medicine and UMDF have jointly authored an editorial that was sent to major newspaper outlets across the United States. It is our hope that...


Alexion Pharmaceuticals and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Stealth BioTherapeutics Corp(NASDAQ:MITO) today announced an agreement for an option to co-develop and commercialize elamipretide for mitochondrial diseases. Currently being evaluated in a Phase...


Stealth BioTherapeutics Presents Data for Elamipretide on Cardiac Function in Barth Syndrome

BOSTON, Oct. 17, 2019 /PRNewswire/ — Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction,...


Parents Decide to Withdraw Treatment Request for Little Charlie Gard

The thoughts and prayers of the entire mitochondrial disease community are with Charlie Gard and his mother and father, Chris Gard and Connie Yates. They have decided to withdraw...


Courtagen Life Sciences Shifts Focus to its Medicinal Cannabis Genetics and Testing Business

Woburn, Mass.–(BUSINESS WIRE)—Courtagen Life Sciences Inc. announced today that the company will be shifting the core focus of its business to medicinal cannabis genetics and testing. As the company...


Reata Announces Top-Line Data from the Dose-Escalation Cohorts of the Phase 2 Motor Study of Omaveloxolone in Patients with Mitochondrial Myopathies

IRVING, Texas, March 01, 2018 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced top-line data from the dose-escalation cohorts of the...


How Calderdale will be showing its support and lighting up green for Mito Awareness Week

Emma Beal, left, and Kerry Ellis (actress and singer best known for her work in musical theatre and subsequent crossover into music) showing her support for #KissGoodbyeToMito The historic...


Stealth BioTherapeutics Presents Data on SBT-272 in Neurodegeneration

BOSTON, Oct. 7, 2019 /PRNewswire/ — Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction,...